Frontier Pharma: Dermatology - Intracellular Signal Transducers and Cytokine Signaling Molecules Dominate Pipeline and First-in-Class Innovation
"The Report Frontier Pharma:
Dermatology - Intracellular Signal Transducers and Cytokine Signaling
Molecules Dominate Pipeline and First-in-Class Innovation provides
information on pricing, market analysis, shares, forecast, and
company profiles for key industry participants. -
MarketResearchReports.biz"
About
Dermatology
Market
Dermatology is a highly diverse therapy
area that deals with diseases of the skin, hair and nails. Over 3,000
distinct dermatological conditions are thought to exist, ranging from
rare autoimmune disorders such as scleroderma, to very common
conditions such as acne vulgaris and atopic dermatitis. For the past
decade the majority of the therapeutic dermatology market has been
saturated and highly genericized, and strongly dominated by small
molecules. There is a significant unmet need for more efficacious and
safer treatment options, as physicians often cite poor efficacy, low
patient compliance and problematic safety profiles as issues with the
long-term use of many available treatments.
Get
Sample copy of this Report @
https://www.marketresearchreports.biz/sample/sample/1217021
Although the scope of dermatological
disorders is diverse in terms of severity, clinical presentation, and
key patient demographics, there is a degree of crossover between many
indications in terms of their underlying pathophysiology. Increased
inflammation and aberrant immune response resulting in skin barrier
dysfunction are commonly shared causes. Infections and dysfunctions
in wound healing are also common causes of dermatological diseases.
Scientific
advancements over the course of recent decades have revealed a broad
range of novel potential molecular targets, enabling the advancement
of a previously stagnant field. This is reflected in the high number
of products being developed, with 961 pipeline products currently in
the dermatology therapy area pipeline.
Analysis indicates that the current
pipeline is following a trend of focusing on innovative biologic
therapies, following the clinical and commercial success of such
therapies in the treatment of psoriasis. There are various biologics
in the pipeline for major skin disorders - including atopic
dermatitis, acne vulgaris and rosacea - for which there is a
significant unmet need in patients with moderate-to-severe
conditions.
Moreover, there is a considerable degree
of innovation present in the therapy area, as there are a total of
197 first-in-class pipeline products in development for
dermatological indications, representing 32% of the 617 pipeline
products for which there is a disclosed molecular target. Many of
these appear promising in terms of safety and efficacy, and carry a
significant potential to strengthen the treatment landscape for
various dermatological conditions.
Scope
- With 961 products in active
development, the pipeline is considerably large. How will pipeline
innovation affect the future dermatology market?
- There are 197 first-in-class products
in the dermatology pipeline. Which of these hold the greatest
potential to improve future disease treatment with regard to their
molecular target?
- The majority of first-in-class products
are in development for indications involving inflammation. Which
first-in-class targets are most promising, and how does the ratio of
first-in-class targets to first-in-class products differ by stage of
development and molecular target class?
- A significant number of first-in-class
products have been identified with no prior involvement in deals. How
do deal frequency and value compare between target families and
molecule types, and which first-in-class programs have not yet been
involved in a licensing or co-development deal?
Reasons to buy
- Understand the current clinical and
commercial landscape. The report includes a comprehensive study of
disease pathogenesis, diagnosis, prognosis and the treatment options
available.
- Visualize the composition of the
dermatology market in terms of dominant molecule types and targets,
highlighting what the current unmet needs are and how they can be
addressed. This knowledge allows a competitive understanding of gaps
in the market.
-
Analyze the dermatology pipeline and stratify by stage of
development, molecule type and molecular target. There are strong
signs in the pipeline that the industry is seeking novel approaches
to treating dermatological diseases, including rare conditions.
- Assess the therapeutic potential of
first-in-class targets. Using proprietary matrices, first-in-class
products have been assessed and ranked according to clinical
potential. The matrices have been split into three categories:
inflammatory diseases, infectious diseases, and wounds/scars.
Promising targets have been reviewed in greater detail.
- Identify commercial opportunities in
the dermatology deals landscape by analyzing trends in licensing and
co-development deals, and producing a list of first-in-class
therapies with no prior involvement in licensing or co-development
deals.
View Report @
Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 5
2.1 Large Therapy Area Characterized by a
High Degree of Pathophysiological Crossover 5
2.2 Biologics and mAbs Growing in
Prominence in Dermatology Therapy Area 5
2.3 Highly Diversified Range of
Innovative Programs in Early Pipeline 5
2.4 Deals Landscape Offers Significant
Investment Opportunities for First-in-Class Products Landscape 6
3 The Case for Innovation 7
3.1 Growing Opportunities for Biologic
Products 8
3.2 Diversification of Molecular Targets
8
3.3 Innovative First-in-Class Development
Remains Attractive 9
3.4 Regulatory and Reimbursement Policy
Shifts Favor First-in-Class Product Innovation 9
3.5 Sustained Innovation 10
3.6 GBI Research Report Guidance 10
4 Clinical and Commercial Landscape 11
4.1 Therapy Area Introduction 11
4.2 Symptoms 11
4.3 Epidemiology and Etiology 12
4.3.1 Atopic Dermatitis 12
4.3.2 Acne Vulgaris 13
4.3.3 Psoriasis 13
4.4 Pathophysiology 14
4.4.1 Atopic Dermatitis 14
4.4.2 Acne Vulgaris 15
4.4.3 Psoriasis 15
4.5 Co-morbidities and Complications 16
4.6 Treatment 17
4.6.1 Topical Corticosteroids 17
4.6.2 Calcineurin Inhibitors 18
4.6.3 Retinoids 18
4.6.4 Systemic Immunosuppressive Agents
19
4.6.5 Biologics 19
4.6.6 Antihistamines 19
4.6.7 Hormonal Therapy 19
4.6.8 Moisturizers 20
4.7 Overview of Marketed Products in
Dermatology 20
5 Assessment of Pipeline Product
Innovation 22
5.1 Pipeline by Stage of Development,
Molecule Type and Molecular Target 22
5.2 First-in-Class Programs Targeting
Novel Molecular Targets 25
6 Signaling Network, Disease Causation
and Innovation Alignment 42
6.1 Complexity of Signaling Networks in
Dermatology 42
6.2 Signaling Pathways and First-in-Class
Molecular Target Integration 42
6.3 First-in-Class Matrix Assessment 42
7 First-in-Class Target and Pipeline
Program Evaluation 48
7.1 Pipeline Programs Targeting
Non-Receptor Tyrosine-Protein Kinase TYK2 48
7.2 Pipeline Programs Targeting Granzyme
B 51
7.3 Pipeline Programs Targeting ORAI1 53
7.4 Pipeline Programs Targeting CC motif
chemokine 11 55
7.5 Pipeline Programs Targeting Potassium
Voltage-Gated Channel Subfamily A Member 3 57
7.6 Pipeline Programs Targeting Toll-like
Receptor 8 59
7.7 Pipeline Programs Targeting CC
Chemokine Receptor Type 6 61
7.8 Pipeline Programs Targeting Targeting
Spleen Tyrosine Kinase 63
7.9 Pipeline Programs Targeting
Galectin-3 65
7.10 Pipeline Programs Targeting Tumor
Necrosis Factor Receptor Superfamily Member 6 67
7.11 Pipeline Programs Targeting
Sphingosine 1-phosphate receptor 4 69
7.12 Pipeline Programs Targeting
Protein-Lysine 6-Oxidase 70
7.13 Pipeline Programs Targeting
Leucine-Rich Repeat-Containing G-Protein Coupled Receptor 6 72
7.14 Conclusion 73
8 Strategic Consolidations 74
8.1 Industry-Wide First-in-Class Deals 74
8.2 Licensing Deals 75
8.2.1 Deals by Region, Value and Year 75
8.2.2 Deals by Stage of Development and
Value 77
8.2.3 Deals by Molecule Type, Molecular
Target and Value 77
8.2.4 List of Deals with Disclosed Deal
Values 79
8.3 Codevelopment Deals 81
Send
An Enquiry Request @
https://www.marketresearchreports.biz/sample/enquiry/1217021
About us
MarketResearchReports.biz is the most
comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Comments
Post a Comment